References
- 1. S. L. Friedman, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, J. Bio. Chem.4 (2000) 2247–2250; https://doi.org/10.1074/jbc.275.4.224710.1074/jbc.275.4.224710644669
- 2. R. T. Hong, J. M. Xu and Q. Mei, Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats, World J. Gastroenterol.12 (2009) 1452–1458; https://doi.org/10.3748/wjg.15.145210.3748/wjg.15.1452266912419322917
- 3. M. Pinzani and K. Rombouts, Liver fibrosis: from the bench to clinical targets, Dig. Liver Dis.4 (2004) 231–242; https://doi.org/10.1016/j.dld.2004.01.00310.1016/j.dld.2004.01.00315115333
- 4. T. Christian, L. F. Scott, S. Detlef and P. Massimo, Hepatic fibrosis: Concept to treatment, J. Hepatol.1 (2015) S15-24; https://doi.org/10.1016/j.jhep.2015.02.03910.1016/j.jhep.2015.02.03925920084
- 5. H. K. Du, F. C. Song, X. Zhou, H. Li and J. P. Zhang, Effect of amygdalin on serum proteinic bio-marker in pulmonary fibrosis of bleomycin-induced rat, Chin. J. Ind. Hygi. Occup. Dis.4 (2010) 260–263.
- 6. X. M. Li, J. H. Peng, Z. L. Sun, H. J. Tian, X. H. Duan, L. Liu, X. Ma, Q. Feng, P. Liu and Y. Y. Hu, Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways, Acta. Pharmacol. Sin.6 (2016) 783–793; https://doi.org/10.1038/aps.2016.3510.1038/aps.2016.35495476727133300
- 7. E. Aghadavod, Amygdalin; is it an anticancer and antitumor agent? Epidemiol. Prev.2 (2016) e22.
- 8. J. Q. Liu, D. Y. Wang and L. Wang, Influences of treatment methods on water absorption of Prunus mongolica seeds and its seedling growth, Chin. For. Sci. Technol.21 (2010) 38–41.
- 9. Y. Q. Ma, Flora of Inner Mongolia, Vol. 3, Hohhot: Inner Mongolia People’s Publishing House, 1989, p. 132.
- 10. S. L. Shi, Y. C. Bai, H. B. Zhou and S. F. Niu, Extraction and determination of content of polysaccharides in Amygdalus mongolica, Lishizhen Med. Mater. Med. Res.24 (2013) 257–258.
- 11. K. Su, S. L. Shi, D. H. Zheng and J. X. Li, Determination of alpha tocopherol content in Amygdalus mongolica by HPLC, Chin. J. Exp. Trad. Med. Form.19 (2013) 70–72.
- 12. J. Q. Guo, W. Z. Wu, M. X. Sheng, S. L. Yang and J. M. Tan, Amygdalin inhibits renal fibrosis in chronic kidney disease, Mol. Med. Rep.5 (2013) 1453–1457; https://doi.org/10.3892/mmr.2013.139110.3892/mmr.2013.139123525378
- 13. H. H. Luo, F. Zhao, F. X. Zhang and L. Ni, Influence of amygdalin on PDG, IGF and PDGFR expression in HSC-T6 cells, Exp. Ther. Med.15 (2018) 3693–3698; https://doi.org/10.3892/etm.2018.588610.3892/etm.2018.5886584410229556259
- 14. Y. S. Zhao, P. S. Wu, H. W. Zhang, X. H. Cheng, S. L. Shi, Q. L. Liu and H. B. Zhou, Studies on dose-effect relationship of n-butanol extracts of Amygdalus mongolica on reducing blood lipid and its chemical constituents, Sci. Technol. Food. Ind.38 (2017) 348–352.
- 15. J. J. Jin, M. Zhong, S. M. Yu and L. Jie, Effect of water extract of Cudrania cochinchinensis on liver fibrosis rat models induced by carbon tetrachloride, Chin. J. Exp. Trad. Med. Formu.22 (2012) 258–262.
- 16. M. P. Ren, Y. Liu, H. Li, M. H. Liu, H. Zhang and J. B. Wu, Study on Aralia saponins in preventing CCL4 induced liver fibrosis in rats, J. Shenyang Pharm. Univ.12 (2013) 958–960.
- 17. S. F. Zhao and Q. C. Kan, Protective effects of Liuweiwuling pian on hepatic fibrosis induced by carbon tetrachloride in rats, Chin. Pharm. Bull.6 (2011) 872–875; https://doi.org/10.3969/j.issn.1001-1978.2011.06.031
- 18. G. W. Newton, E. S. Schmidt, J. P. Lewis, E. Conn and R. Lawrence, Amygdalin toxicity studies in rats predict chronic cyanide poisoning in humans, West J. Med.2 (1981) 97–103; https://doi.org/10.1620/tjem.133.48110.1620/tjem.133.4817256742
- 19. Y. A. Lee and S. L. Friedman, Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C? Antiviral. Res.107 (2014) 23–30; https://doi.org/10.1016/j.antiviral.2014.03.01210.1016/j.antiviral.2014.03.012405074424726738
- 20. J. P. Li, Y. Gao, S. F. Chu, Z. Zhang, C. Y. Xia, Z. Mou, X. Y. Song, W. B. He, X. F. Guo and N. H. Chen, Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis, Acta. Pharmacol. Sin.8 (2014) 1031–1044; https://doi.org/10.1038/aps.2014.4110.1038/aps.2014.41412571124976156
- 21. S. Yamada and C. Hirayama, Clinical significance of serum hydroxyproline-containing peptides with special reference to hyproprotein, Eur. J. Clin. Invest.2 (2010) 129–133; https://doi.org/10.1111/j.1365-2362.1983.tb00077.x10.1111/j.1365-2362.1983.tb00077.x6409636
- 22. G. G. Xu, C. Y. Luo, S. M. Wu and C. L. Wang, The relationship between staging of hepatic fibrosis and the levels of serum biochemistry, Hepatobiliary Pancreat, Dis. Int.2 (2002) 246–248; https://doi.org/CNKI:SUN:GJGD.0.2002-02-019
- 23. S. P. You, J. Zhao, L. Ma, M. Tudimat, S. L. Zhang and T. Liu, Preventive effects of phenylethanol glycosides from Cistanche tubulosa on bovine serum albumin-induced hepatic fibrosis in rats, J. Pharm. Sci.1 (2015) 1–13; https://doi.org/10.1186/s40199-015-0135-410.1186/s40199-015-0135-4467372126646297
- 24. J Liu, J. Y. Wang and Y. Lu, Serum fibrosis markers in diagnosing liver fibrosis, Chin. J. Intern. Med.6 (2006) 475–477.
- 25. S. Clichici, C. Catoi, T. Mocan, A. Filip, C. Login, A. L. Nagy, D. Doina, N. Decea, C. Gherman, R. Moldovan and A. Muresan, Non-invasive oxidative stress markers for liver fibrosis development in the evolution of toxic hepatitis, Acta Physiol. Hung.98 (2011) 195–204; https://10.1556/APhysiol.98.2011.2.1110.1556/APhysiol.98.2011.2.1121616778
- 26. H. B. Tan, Q. He, R. G. Li, and F. F. Lei and X. Lei, Trillin Reduces Liver Chronic Inflammation and Fibrosis in Carbon Tetrachloride (CCl4) Induced Liver Injury in Mice, Immunol. Commun.45 (2016) 371–382; https://doi.org/10.3109/08820139.2015.113793510.3109/08820139.2015.113793527219527
- 27. T. A. Wynn, Cellular and molecular mechanisms of fibrosis, J. Pathol. 2 (2010) 199–210; https://doi.org/10.1002/path.227710.1002/path.2277269332918161745
- 28. C. J. Parsons, T. Motoki and R. A. Rippe, Molecular mechanisms of hepatic fibrogenesis, J. Gastroenterol. Hepatol.1 (2007) S79–84; https://doi.org/10.1111/j.1440-1746.2006.04659.x10.1111/j.1440-1746.2006.04659.x17567474
- 29. Y. M. Yang and E. Seki, TNFα in liver fibrosis, Curr. Pathobiol. Rep.4 (2015) 253–261; https://doi.org/10.1007/s40139-015-0093-z10.1007/s40139-015-0093-z469360226726307
- 30. A. Mehra and J. L. Wrana, TGF-β and the Smad signal transduction pathway, Biochem. Cell Biol.5 (2002) 605–622; https://doi.org/10.1139/o02-16110.1139/o02-16112440701
- 31. F. Y. Xu, C. W. Liu, D. D. Zhou and L. Zhang, TGF/SMAD Pathways and its regulation in hepatic fibrosis, J. Histochem. Cytochem. 3 (2016) 157–167; https://doi.org/10.1369/002215541562768110.1369/0022155415627681481080026747705